Powdered Chloroquine Diphosphate CAS 50-63-5 For Novel Coronavirus Pneumonia

Basic Information
Place of Origin: CHINA
Brand Name: MOSINTER
Certification: COA
Model Number: Pneumonia Treatment Drugs - 1
Minimum Order Quantity: 25KGS
Price: Negotiation
Packaging Details: Aluminum foil bag , fiber can , kraft paper bag , plastic drum , 1kg/ bag or 25kg/ drum or as required
Delivery Time: Within 7 days
Payment Terms: T/T, Western Union
Supply Ability: 200-300 MTS/month
Detail Information
Name: Chloroquine Diphosphate CAS: 50-63-5
Form: Powder Molecular Formula: C18H32ClN3O8P2
Molecular Weight: 515.86 Type: Pneumonia Treatment Drugs
High Light:

drugs used to treat pneumonia


chloroquine diphosphate

Product Description

Chloroquine diphosphate CAS 50-63-5 Pneumonia Treatment Drugs




This product is white crystalline powder, odorless and bitter. The color changes with light and the aqueous solution shows acid reaction. This product is soluble in water, almost insoluble in ethanol, chloroform and ether.

The melting point is 193-196 ℃, and it decomposes at the same time.




Item Standard Result
Characters A white or almost white crystalline powder Conform
Melting point One melting at about 195°C 196°C
Identification Positive Conform
Solutions Complies with test Conform
Appearance of solution BY5 OR GY5 max GY5
PH(10% w/v) 3.8-4.3 4.2
Related substance one spot 1.0% max Conform
Any other spot 0.5% max Conform
Heavy metals 20ppm max 10ppm
Water 2.0% max 0.6%
Assay 98.5%~101.0% 99.6%




1. Recommended time: on February 17, 2020, sun Yanrong, deputy director of the biological center of the Ministry of science and technology, said at a press conference held by the joint prevention and control mechanism of the State Council that in clinical practice, the drug group of chloroquine phosphate was superior to the control group in terms of a series of indicators, such as the rate of severe illness, antipyretic phenomenon, the time of improving the image of the lung, the time and rate of turning negative of viral nucleic acid, and the shortening of the course of disease Group.


2. expert evaluation: novel coronavirus pneumonia was used to evaluate the efficacy of chloroquine phosphate in the treatment of Zhong Nanshan's New Zealand's crown pneumonia. It is considered that "the drug is an old drug that has been on the market for many years, and the safety of the drug for the treatment of a wide range of people is controllable. Based on the novel coronavirus pneumonia treatment, the results of the study conducted by the previous clinical institutes can be effective.


"Chloroquine phosphate is not enough for a specific drug, but it has therapeutic effect and little side effect, which is worth studying and discussing," Zhong Nanshan said in a question from a media reporter on February 18


3. Drug introduction: chloroquine phosphate has been used in the treatment of malaria since the 1940s, and then in the treatment of rheumatoid arthritis.


How does chloroquine phosphate have antiviral effect? First, because chloroquine can change the pH value of the endophage, it has a significant inhibitory effect on the virus infection that invades the cells through the endocytosis pathway; second, chloroquine can affect the virus replication by inhibiting the gene expression of the virus; in addition, as a good autophagy inhibitor, chloroquine can interfere with the virus infection and replication by influencing the autophagy reaction.


4. stage of development novel coronavirus pneumonia treatment phase.


Our strengths:


We can customize according to customer's requirement.

If you have any question pls mail us or call us.


Contact Details

Phone Number : +86 18989305995

WhatsApp : +18989305995